Oasmia expands the Management Team Apr 10, 2019 02:00AM
Oasmia Pharmaceutical AB receives positive opinion from the European Medicines Agency to add efficacy data to the approved Apealea® product information Mar 25, 2019 03:00AM
Oasmia announces a prospectus regarding admission to trading of new shares Mar 18, 2019 11:10AM
Oasmia Pharmaceutical Strengthens its Management Team and Organization Mar 6, 2019 02:30AM
Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019 Jan 22, 2019 04:00AM


Jan 21, 2019 02:30AM Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
Jan 15, 2019 07:13AM Oasmia Pharma (OASM) Reports EMA Validates Type II Variation Application to Add Efficacy Data to Approved Apealea Product Information
Jan 15, 2019 02:30AM European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information
Jan 15, 2019 02:00AM European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information
Nov 29, 2018 02:00AM Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea®
Nov 23, 2018 05:52AM Oasmia Pharma (OASM) Secures European Commission Approval for Apealea (paclitaxel micellar) in the EU
Nov 22, 2018 05:58AM Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union
Nov 20, 2018 07:00AM New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Nov 20, 2018 02:30AM New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Nov 20, 2018 02:00AM New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
Oct 3, 2018 07:00AM Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Oct 3, 2018 03:00AM Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Oct 3, 2018 02:00AM Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma
Sep 21, 2018 07:20AM Oasmia Pharma (OASM) Receives Positive CHMP Opinion for Apealea
Sep 21, 2018 07:20AM Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union
Sep 21, 2018 03:20AM Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union
May 30, 2018 11:45AM Nexttobe Extends Loan to Oasmia Pharmaceutical
May 21, 2018 02:30AM Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
May 20, 2018 10:30PM Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
Feb 19, 2018 02:30AM Oasmia Pharmaceutical’s Docecal program achieves significant development milestone
Jan 8, 2016 10:00AM Oasmia Pharmaceutical to Ring the Nasdaq Stock Market Opening Bell